Quick Takeaways: Why It Matters? BioTesserae’s BTC-001, a PD‑1–targeting single‑domain antibody for canine cancer, showed good tolerability in healthy dogs in a single‑ascending‑dose study, with doses up to three times the anticipated therapeutic level. Ins...
Quick Takeaways: Why It Matters? The collaboration gives Kyoritsu access to cutting-edge microbiome and enzyme engineering capabilities, helping it move beyond traditional pharmaceuticals into differentiated biological solutions. For bitBiome, part...
